BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

BACKGROUND: The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which patients derive most benefit. In this study, we determine the prognostic value of B...

Descripción completa

Detalles Bibliográficos
Autores principales: Liefaard, M. C., van der Voort, A., van Ramshorst, M. S., Sanders, J., Vonk, S., Horlings, H. M., Siesling, S., de Munck, L., van Leeuwen, A. E., Kleijn, M., Mittempergher, L., Kuilman, M. M., Glas, A. M., Wesseling, J., Lips, E. H., Sonke, G. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280902/
https://www.ncbi.nlm.nih.gov/pubmed/37337299
http://dx.doi.org/10.1186/s13058-023-01664-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280902/
https://www.ncbi.nlm.nih.gov/pubmed/37337299
http://dx.doi.org/10.1186/s13058-023-01664-x

Ejemplares similares